In adherence to strict Non-Disclosure Agreements, Sedulo is unable to disclose identifiable information regarding our clients.
When a rising competitor began making bold AI-centric claims, our client knew words weren’t enough, but facts were missing. Through buy-side research, we exposed that behind the AI messaging was an offshore manual data entry engine, arming the client with truthful insight to sharpen positioning, arm sales, and challenge false narratives.
A top pharmaceutical company partnered with Sedulo Group to leverage pharma competitive intelligence and outmaneuver competitors in a high-stakes product launch.
Entering a new market without the right intelligence is a costly risk. Learn how Sedulo Group equips companies with deep competitor, customer, and market insights to build confident, data-driven market entry strategies
The Situation A well-established technology provider pivoted into a new product vertical and quickly encountered a need for sharper positioning against a key incumbent. With hypotheses around competitor pricing and customer sentiment already forming internally, the company required third-party validation and deeper competitive insight to guide its marketing and sales strategy. To confidently move forward, the client partnered with Sedulo
A global technology company partnered with Sedulo Group to gain validated, actionable intelligence on competitor pricing, packaging, and value propositions across payments, identity, and compliance. Through targeted buy-side research and strategic analysis, Sedulo delivered detailed insights into competitor strategies and product differentiation. As a result, the client optimized pricing, sharpened its value propositions, and strengthened internal alignment, driving improved market performance and competitive advantage.
Sedulo crafted an early-warning monitoring program for a pharma leader focused on Parkinson’s stage therapies. Through secondary intelligence (press releases, clinical data) and primary interviews with competitor personnel, the team flagged key R&D moves, enabling the client to pivot proactively in a fast-evolving treatment space
